NextCell Pharma publishes its Interim Report 2 2024/2025

April 25, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second Quarter (2024-12-01 to 2025-02-28)

Operating income amounted to 3,417 (2,405) TSEK, of which Cellaviva contributed 3,248 (2,334) TSEK.
Net sales amounted to 3,248 (2,334) TSEK.
Profit/loss after financial items amounted to -8,198 (-10,093) TSEK.
Earnings per share* were -0.11 (-0.29) SEK.
Cash and cash equivalents amounted to 26,338 (30,393) TSEK.
Equity ratio** amounted to 83 (79) percent.

First Half Year (2024-09-01 to 2025-02-28)

Operating income amounted to 6,281 (7,099) TSEK, of which Cellaviva contributed 6,077 (6,580) TSEK.
Net sales amounted to 6,077 (6,580) TSEK.
Profit/loss after financial items amounted to -16,240 (-19,889) TSEK.
Earnings per share* were -0.40 (-0.58) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first half year of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 28 February 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the second quarter

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from theProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," comment- ed Mathias Svahn, CEO.
Mid Februari NextCell announced that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, had been treated.

Significant events after the reporting period

At the end of March NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr Lindsay Davies had been elected to the board of ATMP Sweden.

In the beginning of April NextCell Pharma announced preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo.
NextCell Pharma announced early April that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, had been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT).
Mid April NextCell Pharma published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discussed with Mathias Svahn questions regarding the latest results from ProTrans-YOUNG.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
RedEye AB is assigned as Certified Adviser.
The company's shares are listed on the Nasdaq First North Growth Market.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2017-09-05

NextCell Pharma AB receives approval from Ethics Committee for Clinical Trial

NextCell Pharma AB (NEXTCL) announced today that the clinical trial application for ProTrans™ has been granted by the Ehtics Committee. ProTrans™ is a stem cell product developed with NextCell's Proprietary Selection Algorithm. The clinical trial is designed to evaluate the safety and efficacy of ProTrans™ for treatment of patients with type 1 diabetes. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska Trial Alliance (KTA), which

Read more Read more

2017-09-04

NextCell Pharma AB to present at several events in next 2 weeks

NextCell Pharma AB (”NextCell”) informs that during the next two weeks there is ample opportunities for (potential) investors to attend presentations given by and conduct discussions with NextCell Pharma personnel. Sessions where NextCell Pharma representatives will be present: · Aktiespararna Södertälje – September 4th 18:30-21:00 · Advanced Medicinal Therapy Products – A game changer in medicine? – Malmoe, September 12th 13:00-17:00 · Nordic Life Science days, Malmoe – September 12th – 14th · Aktiespararna Burlöv – September 13th 19:00-21:00 During these meetings

Read more Read more

2017-08-10

NextCell Pharmas first delivery of ProTrans™

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM.

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM....

Read more Read more

2017-08-08

Stem cell company NextCell Pharma receives approval from Ethics Committee

NextCell Pharma AB (NEXTCL) announced today that approval has been obtained from the Ethics Testing Board EPN, to develop assays from umbilical cord tissue. The collection is performed by regular staff at the clinic at Karolinska University Hospital in Huddinge. The project is conducted by Edvard Smith, Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet, and one of the founders of the Company. The results may be included in the Company's proprietary intellectual property regarding ProTrans. ProTrans is developed for stem cell therapies for

Read more Read more

2017-07-31

NextCell Pharma updates on its current situation in its first quarterly report

NextCell Pharma AB (”NEXTCL”, “NextCell”) today, released its first quarterly report (April-June) since its introduction on Aktietorget. Following the issue in July, and after payment of study drug the Company has approximately SEK 20 million in cash, while the "burn rate" for the reporting period (April-June) was 3.5 MSEK (listing on Aktietorget occurred after the closing of this quarterly report). During the reporting period NextCell Pharma has recruited Leo Groenewegen, who took up the position of CFO. Besides his duties as CFO, Leo Groenewegen, together with Chairman Anders Essen-Moller,

Read more Read more

2017-07-24

NextCell Pharma AB submits clinical trial application for its drug candidate ProTrans™

NextCell Pharma AB ("NextCell") announced today that a clinical trial application for ProTrans™, a stem cell product developed with NextCell's Proprietary Selection Algorithm, has been submitted to the Medical Products Agency (Läkemedelsverket). The study is planned to evaluate the safety and efficacy of ProTrans™ in adult patients with type 1 diabetes diagnosed within two years. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska

Read more Read more

2017-07-19

Disclosure notice: NextCell Pharma AB’s Chairman of the Board acquires additional shares

NextCell Pharma AB (”NextCell”) announces today, on July 19th 2017, that Chairman of the Board, Anders Essen-Möller, has acquired 263.020 shares in the company. Before the acquisition, Essen-Möller held 737.033 shares, equivalent to approximately 8.74 percent of the votes and capital. After the acquisition, Essen-Möller holds 1.000.053 shares, equivalent to approximately 11.76 percent of the votes and capital in NextCell.

Read more Read more

2017-07-13

First day of trading in stem cell company NextCell Pharma AB

NextCell Pharma AB (”NextCell”) announces today that trading with its shares and warrants of series TO 1 will commence today at the AktieTorget stock exchange. The shares will be traded under the name “NEXTCL” with the corresponding ISIN code SE009723125. The warrants will be designated with the name “NEXTCL TO 1” and ISIN code SE009888795. NextCell develops stem cell therapies, where stem cells from donated umbilical cords can treat patients who are not family of the donor. The cells are developed with NextCell's proprietary method and the company's first product, ProTrans™, is intended for

Read more Read more